BIAF
bioAffinity·NASDAQ
--
--(--)
--
--(--)
bioAffinity (BIAF) Company Profile
Bioaffinity Technologies, Inc.
A company that develops proprietary noninvasive diagnostic tests and cancer therapeutics to diagnose early-stage cancer
Medical instruments
03/26/2014
09/01/2022
NASDAQ Stock Exchange
57
12-31
Common stock
3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217
Develops noninvasive lung cancer and lung disease diagnostics.
BioAffinity Technologies, Inc., was incorporated as a Delaware corporation on March 26, 2014. The company develops non-invasive diagnostic tests that use flow cytometry and artificial intelligence-driven analysis for early-stage lung cancer and other respiratory diseases. Its main commercial testing product, CyPath Lung, is offered through its CAP-accredited laboratory subsidiary and is also advancing therapeutic research for cancer treatment.
